Oleoylethanolamide supplementation in women with the poly cystic ovarian syndrome

Phase 2

• Conditions: Poly cystic ovarian syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20141025019669N20
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

The patients who are 18-45 years old diagnosed with the poly cystic ovarian syndrome
Having at least two criteria from Rotterdam's three criteria to diagnose this syndrome;
BMI of less than 30
Signed consent by the patient

Exclusion Criteria

Pregnancy; lactation and menopause;
Infectious disease; inflammatory disease; Cushing's syndrome; adrenal gland tumor; hypothyroidism; increased prolactinemia; acromegaly; diabetes and cancer;
Hormone therapy over the past three months;
Taking antioxidant supplements over the past three months,
Drug use over the past three months includes contraceptives; glucocorticoids; lipid-lowering drugs and weight loss drugs.

Study & Design

• Study Type: interventional
• Study Design: Not specified